According to Yahoo!Finance, “Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver.”
Worth noting is the point when Delcath Systems reached a decline of –99% from the peak by June 2014. That means that for the last 4 years, the stock has been trading –99% below the peak.
The Study of Failure
"Investing is 'a business of making mistakes--the only difference between the winners and the losers is that the winners make small mistakes while the losers make disasterous mistakes. (Russell, Richard. Dow Theory Letters. February 6, 1991. page 2.)'"